Dosing and uses of Alcortin, Vytone (hydrocortisone/iodoquinol)
Adult dosage forms and strengths
hydrocortisone/iodoquinoL
cream
- 1%/1%
- 2%/1%
Dermatoses
Apply to affected area TID/QId
Other Indications & Uses
Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo
Pediatric dosage forms and strengths
hydrocortisone/iodoquinoL
cream
- 1%/1%
- 2%/1%
Dermatoses
<12 years: Safety & efficacy not established
12 years or older: Apply to affected area TID/QId
Alcortin, Vytone (hydrocortisone/iodoquinol) adverse (side) effects
Frequency not defined
Skin atrophy
Striae
Acneform lesions
Pigmentation changes
HPA suppression (with higher potency used >2 wk)
Warnings
Contraindications
Hypersensitivity
Cautions
Chronic topical corticosteroid therapy may interfere with growth and development in children
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity
External use only
Use on extensive surface area or with occlusive dressing may increase systemic absorption and possibly toxicity
Pregnancy and lactation
Pregnancy category: C
Lactation: not known whether either drug applied topically enters breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
